Sensitivity of Leishmania viannia panamensis to pentavalent antimony is correlated with the formation of cleavable DNA-protein complexes

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 8, 1998, Pages 1990-1995

  Lucumi, Armando ^a   Robledo, Sara ^b   Gama, Vivian ^b   Saravia, Nancy G ^a,b,c  

^a UNIVERSIDAD DEL VALLE   (Colombia)

^b CENTRO INTERNACIONAL DE ENTRENAMIENTO E INVESTIGACIONES MÉDICAS CIDEIM   (Colombia)

^c NONE   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY DERIVATIVE; BL 06916; BL 09186; CAMPTOTHECIN; MEGLUMINE ANTIMONATE; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ARTICLE; CASE REPORT; DNA PROTEIN COMPLEX; DOSE RESPONSE; DRUG EFFECT; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEISHMANIA; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN STABILITY; REINFECTION; RELAPSE;

EID: 0031926844     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.8.1990     Document Type: Article

References (23)

1. Atchinson, J., and S. D. Silvey. 1957. The generalization of probit analysis to the case of multiple responses. Biometrika 44:131-140.
2. Berman, J. D., D. Waddell, and B. D. Hanson. 1985. Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate. Antimicrob. Agents Chemother. 27:916-920.
3. Berman, J. D. 1988. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev. Infect. Dis. 10:560-586.
4. Bodley, A. L., and T. Shapiro. 1995. Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on Trypanosomes and Leishmania. Proc. Natl. Acad. Sci. USA 92:3726-3730.
5. Bosque, F., G. Milon, L. Valderrama, and N. G. Saravia. Permissivity of human monocytes and monocyte-derived macrophages to infection by promastigotes. J. Parasitol., in press.
6. Callahan, H. L., and S. M. Beverley. 1991. Heavy metal resistance: a new role for P-glycoproteins in Leishmania. J. Biol. Chem. 266:18427-18430.
7. Chakraborty, A. K., and H. K. Majumder. 1988. Mode of action of pentavalent antimonials: specific inhibition of type I DNA topoisomerase of Leishmania donovani. Biochem. Biophys. Res. Commun. 152:605-612.
8. Ephros, M., E. Waldman, and D. Zilberstein. 1997. Pentostam induces resistance to antimony and the preservative chlorocresol in Leishmania donovani promastigotes and axenically grown amastigotes. Antimicrob. Agents Chemother. 41:1064-1068.
9. Ferreira-Pinto, K. C., A. L. Miranda, C. Anacleto, A. P. S. M. Fernandes, M. C. B. Abdo, M. L. Petrillo, and E. S. A. Moreira. 1996. L. (V.) guyanensis isolation and characterization of glucantime-resistant cell lines. Can. J. Microbiol. 42:944-949.
10. Franke, E. D., F. S. Wignall, M. E. Cruz, E. Rosales, A. A. Tovar, C. M. Lucas, and J. D. Berman. 1990. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann. Intern. Med. 133:934-940.
11. Gramiccia, M., L. Gradoni, and S. Orsini. 1992. Decreased sensitivity to meglumine antimoniate (Glucantime®) of Leishmania infantum isolated from dogs after several courses of drug treatment. Ann. Trop. Med. Parasitol. 86:613-620.
12. Grogl, M., T. M. Thomason, and E. D. Franke. 1992. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am. J. Trop. Med. Hyg. 47:117-126.
13. Gutteridge, W. E., and G. H. Coombs. 1977. Biochemistry of parasitic protozoa. MacMillan Press, London, United Kingdom.
14. Hsiang, Y. H., and L. F. Liu. 1988. Identification of mammalian DNA topoisomerase I as an intracellular target of anticancer drug camptothecin. Cancer Res. 48:1722-1726.
15. Jackson, J. E., J. D. Tally, and W. Y. Ellis. 1990. Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania sp. from patients unresponsive to pentavalent antimony therapy. Am. J. Trop. Med. Hyg. 90:464-480.
16. Marsden, P. D. 1986. Mucosal leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 80:859-876.
17. Palumbo, M., M. Mabilia, and A. Pozzan. 1994. Conformational properties of topoisomerase II inhibitors and sequence specificity of DNA cleavage. J. Mol. Recognit. 7:227-231.
18. Roberts, W. L., and P. M. Rainey. 1993. Antileishmanial activity of sodium stibogluconate fractions. Antimicrob. Agents Chemother. 37:1842-1846.
19. Robledo, S., A. Z. Valencia, and N. G. Saravia. Sensitivity to Glucantime® of Leishmania Viannia isolated from patients prior to treatment. Submitted for publication.
20. Saravia, N. G., K. Weigle, I. Segura, S. Holmes, S. Pacheco, L. A. Labrada, and A. Goncalves. 1990. Recurrent lesions in human Leishmania braziliensis reactivation or reinfection? Lancet 336:398-402.
21. Saravia, N. G., I. Segura, C. Santrich, A. F. Holguín, L. Valderrama, and C. B. Ocampo. 1998. Epidemiologic, genetic and clinical associations among phenotypically distinct populations of Leishmania Viannia in Colombia. Am. J. Trop. Med. Hyg.59:86-94.
22. Weigle, K., C. Santrich, F. Martinez, L. Valderrama, and N. G. Saravia. 1993. Epidemiology of cutaneous leishmaniasis in Colombia: environmental and behavioral factors for infection, clinical manifestations and pathogenicity. J. Infect. Dis. 168:709-714.
23. Weigle, K., and N. G. Saravia. 1996. Natural history, clinical evolution and the host-parasite interaction in New World cutaneous leishmaniasis. J. Clin. Dermatol. 14:433-450.